Catheter Precision to Attend the Annual European Heart Rhythm Association Conference
Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026. The company said it will use the event to share new data, engage key opinion leaders and educate physicians and distributors about LockeT after CE Mark receipt.
This appearance is the company's first large European conference since LockeT received CE Mark clearance and aims to support expanded product use and commercial momentum.
Details
News Market Reaction – VTAK
On Apr 8, the day this news came out, VTAK closed 1.73% below the previous close.
Data tracked by StockTitan Argus for the Apr 8 session.
Key Figures
- EHRA conference dates
- April 12–14, 2026
- European Heart Rhythm Association conference in Paris
Historical Context
-
Peer-reviewed LockeT study in 139 patients showing strong procedural outcomes.
-
Engaged advisor to market electrophysiology business and refocus on Flyte platform.
-
Reported revenue growth but significant net loss while outlining dual-platform strategy.
-
Announced expansion of Vision Jet Hops regional platform and fleet growth plans.
-
Launched Flyte Hops Florida with strong initial bookings and fleet expansion goals.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
european heart rhythm association medical
ehra medical
european society of cardiology medical
ce mark regulatory
electrophysiology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026.
EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right.
David Jenkins, CEO of Catheter Precision, says, “Conferences continue to be a top priority for Catheter Precision. It is at these events that we can share our newest data and meet with key opinion leaders in the electrophysiology field. EHRA 2026 is exciting as this is the first large European conference we are attending since receipt of the CE Mark for LockeT. This is the perfect opportunity to educate new physicians and distributors about LockeT and continue the forward momentum and expanded product use.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.